Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
CVS to close ‘select’ pharmacies in Target stores starting in February
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Bertha Coombs joins ‘Closing Bell’ to report on the announcement from CVS on their plan to close select pharmacies inside Target locations beginning in February.
Watch Tuesday’s full episode of Fast Money — January 10, 2024
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email “Fast Money” is America’s post-market show. Hosted by Melissa Lee and a roundtable of top traders, “Fast Money” breaks through the noise of the day, to bring you the actionable news that matters most to investors.
Shari Redstone launches formal auction of National Amusements: Report
CNBC’s Andrew Ross Sorkin reports on the latest news.
Watch CNBC’s full interview with Ritholtz’s Josh Brown and SoFi’s Liz Young
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Josh Brown, Ritholtz Wealth Management CEO and Liz Young, SoFi, join ‘Closing Bell’ to discuss the Nasdaq’s momentum, big bank earnings expectations and their market outlook.
Markets could ‘look past’ a temporary US lockdown: Analyst
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Andrew Harmstone from Morgan Stanley Investment Management believes a credible coronavirus policy from the Biden team will be able to mitigate any downside from a potential temporary lockdown to stem the pandemic. 00:40 Mon, Nov 9 20203:03 AM EST
SEC and X investigate fake post
CNBC’s Eamon Javers joins ‘Power Lunch’ to discuss the SEC and X investigating a fake SEC post.
